This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Charlotte, NC-based Albemarle Corporation is a premier specialty chemicals company with leading positions in attractive end markets globally. It is a leading producer of highly-engineered specialty chemicals geared to meet customer requirements across a bevy of end markets including petroleum refining, consumer electronics, energy storage, construction and automotive.
Albemarle Corporation (ALB) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Albemarle (ALB) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Albemarle Corporation (ALB) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Albemarle (ALB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Albemarle's Q4 Earnings and Sales Miss Estimates on Lower Pricing
by Zacks Equity Research
Lower prices and volumes in the Energy Storage segment hurt ALB's top line in Q4.
Albemarle (ALB) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Albemarle (ALB) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Albemarle (ALB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Albemarle (ALB) delivered earnings and revenue surprises of -122.45% and 6.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Huntsman (HUN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Huntsman (HUN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unlocking Q4 Potential of Albemarle (ALB): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Albemarle (ALB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Kinross Gold to Post Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
KGC is likely to have benefited from higher average realized gold prices in the fourth quarter.
Albemarle (ALB) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Albemarle (ALB) settling at $79, representing a -1.1% change from its previous close.
DuPont Warms Up to Q4 Earnings: What's in the Offing for the Stock?
by Zacks Equity Research
DD is expected to have benefited from innovation, productivity actions and the acquisitions of the Spectrum Plastics Group and Donatelle Plastics in Q4.
Albemarle to Post Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
ALB is likely to have benefited from healthy lithium volumes and its cost actions amid headwinds from softer lithium market prices in Q4.
Albemarle (ALB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Albemarle (ALB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Albemarle (ALB) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
The latest trading day saw Albemarle (ALB) settling at $86.28, representing a +0.44% change from its previous close.
4 Chemical Stocks Poised to Outshine Q4 Earnings Estimates
by Anindya Barman
DuPont (DD), Eastman Chemical (EMN), Avient (AVNT) and Albemarle (ALB) are likely to have benefited from cost and productivity actions amid soft demand in Q4.
Albemarle Corporation (ALB) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Albemarle (ALB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Albemarle (ALB) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
In the latest trading session, Albemarle (ALB) closed at $88.76, marking a -1.16% move from the previous day.
Albemarle (ALB) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Albemarle (ALB) concluded the recent trading session at $94.32, signifying a -0.87% move from its prior day's close.
Albemarle Corporation (ALB) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Albemarle (ALB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Albemarle (ALB) Stock Moves -0.97%: What You Should Know
by Zacks Equity Research
Albemarle (ALB) concluded the recent trading session at $86.53, signifying a -0.97% move from its prior day's close.
Here's Why Albemarle (ALB) Fell More Than Broader Market
by Zacks Equity Research
Albemarle (ALB) reachead $85.23 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Albemarle Corporation (ALB) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Albemarle (ALB). This makes it worthwhile to examine what the stock has in store.
Albemarle (ALB) Stock Moves -0.96%: What You Should Know
by Zacks Equity Research
Albemarle (ALB) reachead $88.29 at the closing of the latest trading day, reflecting a -0.96% change compared to its last close.
Albemarle (ALB) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Albemarle (ALB) reachead $89.15 at the closing of the latest trading day, reflecting a -0.93% change compared to its last close.
Zacks Investment Ideas feature highlights: DexCom and Albemarle
by Zacks Equity Research
DexCom and Albemarle are part of the Zacks Investment Ideas article.
Albemarle (ALB) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Albemarle (ALB) closed at $88.65 in the latest trading session, marking a -0.3% move from the prior day.